Join to View Full Profile
20 York StT-209New Haven, CT 06510
Phone+1 203-688-2259
Fax+1 203-688-5599
Dr. Buza is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Yale-New Haven Medical CenterResidency, Pathology-Anatomic and Clinical, 2006 - 2009
University of Pécs Medical SchoolClass of 1999
Certifications & Licensure
CT State Medical License 2008 - 2025
American Board of Pathology Pathology - Anatomic
Publications & Presentations
PubMed
- Primary Endometrial Gastric (Gastrointestinal)-type Mucinous Adenocarcinoma: A Detailed Clinicopathologic and Molecular Analysis of 27 Cases.Harsimar Kaur, Lawrence Hsu Lin, David L Kolin, Andre Pinto, Carlos Parra-Herran
The American Journal of Surgical Pathology. 2025-03-11 - 1 citationsTargetable ERBB2/HER2 Mutations in Gynecologic Malignancies: Clinicopathological, Immunohistochemical, and Molecular Correlations.Padmini A Manrai, Austin McHenry, Tong Sun, Alessandro D Santin, Elena Ratner
International Journal of Gynecological Pathology. 2025-03-01 - Gestational trophoblastic disease: STR genotyping for precision diagnosis.Krasimira A Rozenova, Natalia Buza, Pei Hui
Expert Review of Molecular Diagnostics. 2025-01-19
Journal Articles
- Phase II Evaluation of Nivolumab in the Treatment of Persistent or Recurrent Cervical Cancer (NCT02257528/NRG-GY002)Alessandro D Santin, Michael Frumovitz, Natalia Buza, Samir Khleif, Elena S Ratner, Roisin E O'Cearbhaill, Michael Birrer, Gynecologic Oncology
- Minimal Microsatellite Shift in Microsatellite Instability High Endometrial Cancer: A Significant Pitfall in Diagnostic InterpretationXinyu Wu, Douglas Rottmann, Olivia Snir, Pei Hui, Natalia Buza, Nature
Press Mentions
- Reproducibility of Scoring Criteria for HER2 Immunohistochemistry in Endometrial Serous Carcinoma: A Multi-Institutional Interobserver Agreement StudyFebruary 3rd, 2021
Study Validates Combination Therapy for Aggressive Endometrial CancerJune 26th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
